Founder of Capstan Therapeutics, UPenn Department of Medicine
Philadelphia
Joined July 2012
- Tweets40
- Following235
- Followers231
- Likes296
Pinned Tweet
Very excited to be a part of this fantastic collaboration and share this study with everybody. I hope this brings us a step closer to addressing the enormous burden of cardiac and other fibrotic diseases.
Thank you to the whole team (including those not on Twitter!)
First Author: @DevBioAcademic
Co-corresponding: @WeissmanLab, Hamideh Parhiz, @Haig_Ag, & @jonepstein1
Collaborators at @AcuitasTx, @carlhjune, and many others.
6/6
Haig Aghajanian retweeted
In Science, researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells.
The approach showed rapid and sustained immune reprogramming in preclinical models, highlighting its promise for treating cancer and autoimmune diseases.
📄: scim.ag/3TuHwJ3
#SciencePerspective: scim.ag/3SXG15Z
ALT Graphic depicting in vivo generation of CAR T cells
Haig Aghajanian retweeted
🏆 Best of #NatMetab2022 | CITATIONS
#14
The @JonEpsteinLab (@PennMedicine) summarize ongoing developments of CAR-based therapies for indications beyond #cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging.
nature.com/articles/s42255-0…
Haig Aghajanian retweeted
“CAR-T made entirely within the body”
Lots of good work ahead to make this a reality! @capstantx @lshawverO @BLLPHD @Haig_Ag
lnkd.in/eQpteQZD
Haig Aghajanian retweeted
@NEJM Fighting Cardiac Fibrosis with CAR T Cells- Clinical Implications of Basic Research "An advance for several reasons" 1) off the shelf CAR T cells 2) transient expression 3) remarkable lipid nanoparticle safety record @PennMedicine @WeissmanLab
@JonEpsteinLab @carlhjune
Haig Aghajanian retweeted
PERSPECTIVE | Aghajanian, Rurik & @JonEpsteinLab (@PennMedicine) summarize the ongoing development of CAR-based therapies for indications beyond cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging. #immunotherapy
nature.com/articles/s42255-0…
Haig Aghajanian retweeted
We are excited to announce 3 new speakers at our LNP-RNA Therapeutics Beyond COVID Virtual Symposium!
Meet Philip Robert from CPI, Adrian Abbotts from @Siemens & @Haig_Ag from @Penn
Click here to register for the 2-Day virtual event: ow.ly/a5U950Ik76P
Haig Aghajanian retweeted
Merging RNA technology and #cardioimmunology to tackle heart fibrosis - some thoughts from @McKinseyLab and us on this exciting new approach by @JonEpsteinLab & colleagues. Check out the full paper at science.org/doi/10.1126/scie… #CardioTwitter
Preview in this issue of CellStemCell: T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR cell.com/cell-stem-cell/full…
Haig Aghajanian retweeted
🆕Review: CAR-based therapies: opportunities for immuno-medicine beyond cancer- by Haig Aghajanian, @DevBioAcademic, @jonepstein1 #immunotherapy @NatMetabolism nature.com/articles/s42255-0…
Haig Aghajanian retweeted
🚨New: Decade-long #leukemia remissions with persistence of CD4+ CAR T-cells demonstrates long-term potential and clonal stability of #CARTCell therapy #tcell #tcellrx #cancer #immunotherapy @PennMedicine @Nature Portfolio nature.com/articles/s41586-0…
Haig Aghajanian retweeted
Researchers @DevBioAcademic @Haig_Ag @WeissmanLab @jonepstein1 and team harnessed #mRNA tech to create therapeutic CAR-T cells (in mice) to treat heart disease.
mRNA shot spawns CAR-T cells in the body to repair heart disease damage | FierceBiotech bit.ly/3fVWpQP
Haig Aghajanian retweeted
In this week's @ScienceMagazine cover story, @DevBioAcademic, @Haig_Ag, @WeissmanLab, Parhiz, @JonEpsteinLab, & al. use CD5-targeted lipid #nanoparticles to generate therapeutic #CARTcells in vivo!
bit.ly/Sci_abm0594
w/ PS by Gao & Chen:
bit.ly/Sci_abn0851
Haig Aghajanian retweeted
JUST OUT: New, off-the-shelf method for generating CAR T cells in vivo developed and tested in mice. bit.ly/3q1KfMe
Haig Aghajanian retweeted
An experimental #mRNA therapy makes CAR-T cells inside the body to target heart fibrosis. The @PennMedicine study marks an important step in developing accessible and affordable "off-the-shelf" personalized immunotherapies. fiercebiotech.com/research/m…
Haig Aghajanian retweeted
#CARTCell Principal Scientist #hiring at Capstan Therapeutics- responsible for setting up and executing on a robust preclinical CAR T program with applications in multiple disease categories, cell types, and indications. lnkd.in/eyH-Mn7v
Well deserved.
BREAKING NEWS:
The 2021 #NobelPrize in Physiology or Medicine has been awarded jointly to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch.”
Maybe this hidden gem is not so hidden anymore...
This Post is from an account that no longer exists. Learn more
Haig Aghajanian retweeted
Our work “A transcriptional switch governs fibroblast activation in heart disease” previously on @biorxivpreprint is now online @Nature. A great team effort @GladstoneInst @dsrivastava_md and all the fantastic collaborators. A new thread /1 👇
nature.com/articles/s41586-0…
Great review by a talented graduate student in our lab Joel Rurik @DevBioAcademic. Immunomodulation and immunotherapy hold great promise for the future of cardiac therapeutics and regenerative medicine.
@CircRes Review Alert! #ImmuneCells and #Immunotherapy for #CardiacInjury and Repair. Learn more at ow.ly/f7FM30rJAKc
@DevBioAcademic
